Compass Therapeutics Inc (NASDAQ: CMPX) stock jumped 6.00% on Friday to $1.59 against a previous-day closing price of $1.50. With 0.86 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.26 million shares. The 52-week range on CMPX shows that it touched its highest point at $5.65 and its lowest point at $1.39 during that stretch. It currently has a 1-year price target of $9.17. Beta for the stock currently stands at 0.38.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CMPX was up-trending over the past week, with a rise of 2.58%, but this was down by -17.62% over a month. Three-month performance dropped to -32.63% while six-month performance fell -49.84%. The stock lost -64.67% in the past year, while it has lost -68.39% so far this year. A look at the trailing 12-month EPS for CMPX yields -0.33 with Next year EPS estimates of -0.44. For the next quarter, that number is -0.09. This implies an EPS growth rate of 10.04% for this year and -32.62% for next year.
Float and Shares Shorts:
At present, 126.30 million CMPX shares are outstanding with a float of 81.72 million shares on hand for trading. On Oct 30, 2023, short shares totaled 2.85 million, which was 2.24% higher than short shares on Sep 28, 2023. In addition to Dr. Thomas J. Schuetz M.D., Ph.D. as the firm’s Co-Founder, CEO & Director, Dr. Vered Bisker-Leib M.D., MBA, Ph.D. serves as its President & COO.
Through their ownership of 64.96% of CMPX’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 32.80% of CMPX, in contrast to 21.75% held by mutual funds. Shares owned by individuals account for 12.37%. As the largest shareholder in CMPX with 5.19% of the stake, Janus Henderson Investors US LLC holds 6,615,938 shares worth 6,615,938. A second-largest stockholder of CMPX, Adage Capital Management LP, holds 6,380,000 shares, controlling over 5.01% of the firm’s shares. Braidwell LP is the third largest shareholder in CMPX, holding 5,954,273 shares or 4.67% stake. With a 2.80% stake in CMPX, the Biotech Growth Trust Plc is the largest stakeholder. A total of 3,571,428 shares are owned by the mutual fund manager. The Vanguard Total Stock Market ETF, which owns about 1.72% of CMPX stock, is the second-largest Mutual Fund holder. It holds 2,187,972 shares valued at 3.94 million. iShares Russell 2000 ETF holds 1.61% of the stake in CMPX, owning 2,052,408 shares worth 3.69 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CMPX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With CMPX analysts setting a high price target of $11.00 and a low target of $8.00, the average target price over the next 12 months is $9.17. Based on these targets, CMPX could surge 591.82% to reach the target high and rise by 403.14% to reach the target low. Reaching the average price target will result in a growth of 476.73% from current levels.
Summary of Insider Activity:
Insiders traded CMPX stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 7 while that of sell transactions has risen to 4 over the past year. The total number of shares bought during that period was 990,000 while 40,535 shares were sold.